LOS ANGELES, Oct. 10, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Endo International plc (“Endo” or the “Company”) (Nasdaq:ENDP) for possible violations of federal securities laws from November 30, 2012 through July 6, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired Endo shares during the Class Period should contact the firm before the October 17, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Endo made false and/or misleading statements, and/or failed to disclose that: Reformulated Opana was not resistant to crushing; that Reformulated Opana was not abuse-deterrent and its use carried an inherent risk of abuse by grinding, snorting, or injecting; that Reformulated Opana was contributing to an opioid public health crisis; and that Endo would ultimately remove Reformulated Opana from the market. Upon release of this information, shares of Endo fell in value materially, which caused investors harm according to the Complaint.
Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethics rules.
Contact:
Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]
http://lundinlawpc.com/


Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Anta Sports Expands Global Footprint With Strategic Puma Stake
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



